Compare · MASI vs NUWE
MASI vs NUWE
Side-by-side comparison of Masimo Corporation (MASI) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASI and NUWE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- NUWE carries a market cap of $2.2M.
- NUWE has hit the wire 8 times in the past 4 weeks while MASI has been quiet.
- MASI has more recent analyst coverage (24 ratings vs 1 for NUWE).
- Company
- Masimo Corporation
- Nuwellis Inc.
- Price
- -
- -
- Market cap
- -
- $2.2M
- 1M return
- +0.93%
- -
- 1Y return
- +25.20%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 0
- 8
- Recent ratings
- 24
- 1
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest MASI
- SEC Form 15-12G filed by Masimo Corporation
- Director Solomon Darlene J. S. returned $542,700 worth of shares to the company (3,015 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- Director Scannell Timothy J returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- Director Lane Wendy E returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director by deputization Politan Capital Management Lp
- Director by deputization Politan Capital Management Lp returned $826,357,140 worth of shares to the company (4,590,873 units at $180.00) (SEC Form 4)
- Chairman of the Board Brennan Michelle returned $1,675,620 worth of shares to the company (9,309 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Accounting Officer Hataishi Paul returned $2,397,060 worth of shares to the company (13,317 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Operations Sampath Anand returned $6,102,180 worth of shares to the company (33,901 units at $180.00), closing all direct ownership in the company (SEC Form 4) to cover taxes
- SEC Form 4 filed by Chief Commercial Officer Meehan Greg Allen (for tax liability)
Latest NUWE
- Nuwellis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Nuwellis Inc.
- Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
- Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
- Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above
- Nuwellis to Report Third Quarter 2026 Financial Results on November 12
- Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
- SEC Form 8-K filed by Nuwellis Inc.
- Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System